Biospecimen Acquisition, Processing, and Classification Unit

生物样本采集、处理和分类装置

• 批准号: 10904039
• 负责人: Ryan C Fields
• 金额: $ 16.97万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-04 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10904039
• 关键词: Address; Animal Model; Atlases; Bioinformatics; Biological Models; Biopsy; Cancer Center; Classification; Clinical; Clinical Data; Collaborations; Collection; Comprehensive Cancer Center; DNA; Data; Data Analyses; Databases; Dedications; Diagnosis; Eligibility Determination; Emerging Technologies; Ensure; Excision; Future; Genomics; Glioblastoma; Goals; Hospitals; Human; Immunologics; In Vitro; Infrastructure; Institution; Institutional Review Boards; Malignant Neoplasms; Metadata; Methodology; Mission; Molecular; Nature; Neoplasm Metastasis; Operative Surgical Procedures; Pancreatic Ductal Adenocarcinoma; Pathogenesis; Patient Recruitments; Patients; Procedures; Program Development; Protocols documentation; Quality Control; RNA; Recurrence; Research; Research Personnel; Resistance; Resources; Sampling; Solid; Specimen; Technology; Testing; Tissue Preservation; Tissue Procurements; Tissues; Universities; Washington; Work; companion diagnostics; design; follow-up; follower of religion Jewish; in vivo; medical schools; neoplastic cell; novel; precision medicine; preservation; programs; prospective; quality assurance; targeted treatment; therapeutic development; therapy resistant; translational oncology; treatment effect; triple-negative invasive breast carcinoma; tumor

Project Summary/Abstract: Biospecimen Unit The over-arching goal of the Biospecimen Unit for the Washington University Human Tumor Atlas Research Center (WU-HTARC) is to collect human tumor biospecimens for use by the Characterization and Data Analysis Units to construct the proposed tumor atlases. Our Biospecimen Unit will procure and bank longitudinal biopsies and excised tumors from 300-375 patients (selected from ~750 recruited patients) with a goal toward studying the transition from primary malignancy to recurrence and metastasis in conjunction with the development of therapeutic resistance in triple negative breast cancer (TNBC), glioblastoma (GBM), and pancreatic ductal adenocarcinoma (PDAC). Each of the three tumors chosen for this study poses unique challenges for both clinicians and researchers. From their often late onset of diagnosis, highly metastatic nature, challenges in achieving complete surgical resection, and primary and acquired resistance to treatment, each of these tumors represents an opportunity identified by the NCI Cancer Moonshot Initiative (CMI) to significantly advance our understanding of cancer and how to intervene on its initiation and progression. To support the overall mission of WU-HTARC, the Biospecimen Unit will perform the following: (1) identification of eligible patients at WU with TNBC, GBM, and PDAC; (2) rigorous and systemic collection of tumors, including longitudinal collection of all patients throughout their treatment course; (3) complete collection of associated clinical data and metadata; and (4) storage and processing of all samples with current and future experimental and analytical pipelines. The Biospecimen Unit will work closely with other Units within WU-HTARC to develop standard operating procedures and to make adjustments in line with the changing technologies.

项目摘要/摘要：生物样本单元 华盛顿大学人类肿瘤图谱研究生物样本组的总体目标 中心（WU-HTARC）收集人类肿瘤生物样本供表征和数据使用 构建建议的肿瘤图谱的分析单元。我们的生物样本部门将采购和储存 对 300-375 名患者（从约 750 名招募的患者中选出）进行纵向活检和切除肿瘤， 目标是研究从原发性恶性肿瘤到复发和转移的转变 三阴性乳腺癌 (TNBC)、胶质母细胞瘤 (GBM) 和 胰腺导管腺癌（PDAC）。本研究选择的三种肿瘤中的每一种都具有独特的特征 临床医生和研究人员面临的挑战。由于诊断往往较晚，且具有高度转移性 性质、实现完全手术切除的挑战以及对治疗的原发性和获得性耐药性， 这些肿瘤中的每一个都代表着 NCI 癌症登月计划 (CMI) 确定的一个机会 显着增进我们对癌症以及如何干预其发生和进展的理解。到 为了支持WU-HTARC的总体使命，生物样本单位将执行以下任务：（1）鉴定 WU 符合资格的 TNBC、GBM 和 PDAC 患者； (2)严格、系统的肿瘤采集，包括 在整个治疗过程中纵向收集所有患者； (3)关联完整集合 临床数据和元数据； (4)当前和未来实验的所有样品的存储和处理 和分析管道。生物样本部门将与 WU-HTARC 内的其他部门密切合作，开发 标准操作程序并根据不断变化的技术进行调整。